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Abstract
Background: Clinical performance targets are intended to improve patient outcomes in chronic
disease through quality improvement, but evidence of an association between multiple target
attainment and patient outcomes in routine clinical practice is often lacking.
Methods: In a national prospective cohort study (ESRD Quality, or EQUAL), we examined
whether attainment of multiple targets in 668 incident hemodialysis patients from 74 U.S. not-for-
profit dialysis clinics was associated with better outcomes. We measured whether the following
accepted clinical performance targets were met at 6 months after study enrollment: albumin (≥4.0
g/dl), hemoglobin (≥11 g/dl), calcium-phosphate product (<55 mg2/dl2), dialysis dose (Kt/V≥1.2),
and vascular access type (fistula). Outcomes included mortality, hospital admissions, hospital days,
and hospital costs.
Results: Attainment of each of the five targets was associated individually with better outcomes;
e.g., patients who attained the albumin target had decreased mortality [relative hazard (RH) = 0.55,
95% confidence interval (CI), 0.41–0.75], hospital admissions [incidence rate ratio (IRR) = 0.67, 95%
CI, 0.62–0.73], hospital days (IRR = 0.61, 95% CI, 0.58–0.63), and hospital costs (average annual
cost reduction = $3,282, P = 0.002), relative to those who did not. Increasing numbers of targets
attained were also associated, in a graded fashion, with decreased mortality (P = 0.030), fewer
hospital admissions and days (P < 0.001 for both), and lower costs (P = 0.029); these trends
remained statistically significant for all outcomes after adjustment (P < 0.001), except cost, which
was marginally significant (P = 0.052).
Conclusion: Attainment of more clinical performance targets, regardless of which targets, was
strongly associated with decreased mortality, hospital admissions, and resource use in hemodialysis
patients.
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Background
Both improvement in the quality of delivered care and its
measurement are of considerable interest to healthcare
providers and researchers [1-3]. In particular, for those
providing care to kidney disease patients, the National
Kidney Foundation began the Kidney Disease Dialysis
Outcomes Quality Initiative (KDOQI) [4] in 1995, "in
keeping with its longstanding commitment to improving
the quality of care delivered to all patients with kidney dis-
ease and the firm conviction that substantial improve-
ments in the quality and outcomes of their care are
achievable." This program has published several clinical
performance guidelines [4], based in part upon evidence
of improved outcomes and in part upon expert judgment,
that address aspects of end-stage renal disease (ESRD)
patient care related to nutrition, bone disease manage-
ment, anemia management, adequacy of dialysis, and vas-
cular access placement.
Higher serum albumin, a marker of better nutrition and
lower inflammatory burden, has been well-established as
a predictor of better survival in dialysis patients [5-10].
Lower levels of calcium-phosphate (Ca-P) product, a
marker of effective bone disease management, have also
been shown to be associated with decreased mortality
[11]. Renal anemia, reflected by low hemoglobin levels
[12-14], and low dialysis doses [15-18] have been associ-
ated with poor outcomes, which are fewer with the place-
ment of a native arteriovenous fistula versus a graft or
catheter [19,20]. It has also been suggested that bringing
hemodialysis patients within guidelines for multiple clin-
ical performance targets may confer greater survival [21].
These guidelines have led to improvement in the process
of kidney disease care, as evidenced by improvement in
clinical performance measures, and have even led to calls
for financial incentives for further improvement [22].
However, whether attainment of accepted clinical per-
formance targets for nutrition, bone disease management,
anemia management, dialysis adequacy, and vascular
access placement by hemodialysis patients have led to
fewer hospitalizations, fewer hospital days, or decreased
hospitalization costs, in addition to better patient sur-
vival, has been less well-studied [23,24]. In addition, the
attainment of multiple clinical performance targets may
or may not confer greater protection than the attainment
of any single target. Thus, we conducted a national study
to examine whether both individual and multiple clinical
performance target attainment in end-stage renal disease
patients was associated with improvement in these clini-
cal outcomes.
Methods
Study design
The ESRD Quality (EQUAL) study was designed to meas-
ure processes of care and outcomes in the Choices for
Healthy Outcomes in Caring for End-Stage Renal Disease
(CHOICE) [25] cohort. The population examined here
consisted of 668 incident hemodialysis patients who were
treated at 74 U.S. not-for-profit, free-standing outpatient
dialysis clinics in 18 states. To be included in this study,
patients had to be treated with hemodialysis and survive
at least 6 months. The CHOICE cohort consisted of 1041
incident dialysis patients (767 hemodialysis, 274 perito-
neal dialysis) enrolled in a national observational study of
treatment effectiveness study at 81 dialysis clinics in 19
states between October 1995 and June 1998. Neither the
CHOICE nor the EQUAL study involved the use of any
intervention. To be eligible, patients had to be older than
18 years of age and speak either English or Spanish.
Median time from dialysis initiation to enrollment was 45
days, with 98% enrolling within 4 months of initial dial-
ysis. Informed consent was obtained from each patient.
Institutional review boards for the Johns Hopkins Univer-
sity School of Medicine and clinical centers approved the
study protocol.
Data collection
Measures of whether patients attained clinical perform-
ance targets at 6 months after enrollment in the study
served as the independent variables for this study. The
clinical performance measures examined included 6-
month values for albumin, hemoglobin, Ca-P product,
and dialysis dose and ascertainment of the type of vascu-
lar access in use at 6 months. Albumin, hemoglobin, cal-
cium, and phosphate levels were obtained from routine
laboratory data. All serum albumin levels were measured
at a central laboratory using the Bromocresol Green
method (CV, 1.1%). Calcium levels were corrected for
albumin [corrected calcium = calcium level + 0.8*(4-albu-
min level)] before Ca-P products were calculated. Vascular
access information was obtained on a subset of individu-
als through review of discharge summaries, dialysis flow
sheets, and dialysis clinic progress notes [26]. Dialysis
dose (Kt/V) was calculated from values of blood urea
nitrogen, pre- and post-dialysis, weight, and dialysis dura-
tion using the Daugirdas formula [27]. The targets we
selected for these measures, which were based upon the
KDOQI Clinical Practice Guidelines [4], were: albumin,
≥4.0 g/dl; hemoglobin, ≥11 g/dl (based upon the lower
limit of the guideline range of 11–12 g/dl); Ca-P product,
<55 mg2/dl2; dialysis dose, Kt/V≥1.2; and vascular access
type, presence of functioning arteriovenous fistula. In
addition to individual targets, the total number of targets
attained was also used as an independent variable. For
total number of targets attained, data were collapsed into
four categories (zero or one target, two targets, three tar-BMC Health Services Research 2007, 7:5 http://www.biomedcentral.com/1472-6963/7/5
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gets, and four or five targets attained). The numbers of
patients attaining no (n = 3) or all five targets (n = 17)
were small. We also examined a subset of targets (albu-
min, Ca-P product, and hemoglobin) that are regularly
measured as part of the usual laboratory panels.
Outcome variables included all-cause mortality, number
of hospitalizations, days hospitalized, and hospitalization
costs. Mortality information was ascertained from clinic
report, medical records, and Centers for Medicare & Med-
icaid Services (CMS; death notification forms and Social
Security records). Follow-up continued until death, trans-
plantation, loss to follow-up, or the last follow-up date of
November 2003. Hospitalization data were obtained
through the United States Renal Data System (USRDS)
[28] and were available through November 2001. Hospi-
talization costs were defined as the amount paid by Medi-
care for hospitalizations; for hospitalizations that were
paid by another insurer, a payment-to-charge ratio, calcu-
lated from those records exclusively paid by Medicare, was
applied to the charges to estimate the Medicare payment.
We also collected data on demographic, laboratory, and
clinical characteristics. Data regarding patient demo-
graphics (age, sex, and race) and socioeconomic status
(education and employment) were collected from a base-
line self-report questionnaire. Laboratory values and
height and weight [used to calculate body mass index
(BMI)] were obtained from clinic records and from the
CMS Medical Evidence report (CMS Form 2728). Comor-
bidity was assessed at baseline using the Index of Coexist-
ent Disease (ICED), a validated measure whose composite
integer score ranges from 0 to 3 (with 3 as the highest
severity level) and is a measure of both the presence and
severity of comorbid conditions [29-32]. The ICED is
derived from the peak scores of the Index of Disease Sever-
ity and the Index of Physical Impairment using an algo-
rithm specific to the ICED. The Index of Disease Severity
consists of 19 categories of medical conditions, with four
levels of severity for each condition. Information for the
IDS was abstracted from dialysis unit records, hospital dis-
charge summaries, medication lists, consultation notes,
diagnostic imaging, and cardiac imaging reports. Two
dialysis nurses, with prior training and experience in using
the ICED, reviewed and scored all charts. The Index of
Physical Impairment is an observer-based assessment of
11 functional domains, each with three severity levels,
completed by a local dialysis nurse familiar with the
patient's level of functioning, with input from a family
member or caregiver, if necessary. Late referral was
defined as less than 4 months between first nephrologist
evaluation and start of dialysis [33]. Frequency of physi-
cian contact and sit-down rounds were as described previ-
ously [34,35]; noncompliance with dialysis was defined
as missing >3% of hemodialysis sessions.
Statistical methods
We first compared patient characteristics by whether
patients attained individual targets and by the total
number of targets they attained using Pearson's χ2 tests for
categorical variables and two-sided t tests or ANOVA for
continuous variables. Observed survival time was assessed
starting at time of patient enrollment and ending at death
or censoring (at transplant, loss to follow-up, or clo-
seout), and we assessed individual cumulative mortality
by whether patients attained targets by calculating overall
crude mortality rates at the average follow-up (2.8 years)
and by using Kaplan-Meier methods. We used Cox pro-
portional hazards models to assess the strength and inde-
pendence of an association between target attainment and
survival. The proportional hazards assumption was not
violated for any of the targets or for the total number of
targets attained (p  > 0.05 by global test of Schoenfeld
residuals). Crude hospitalization rates were calculated,
and Poisson regression models were used to assess the
relation between target attainment and hospitalization
(incidence rate ratio). Linear regression was used to assess
the association between attainment of targets and hospi-
talization (after logarithmic transformation) costs per
year. For all regression models, attainment of individual
targets, the subset of three laboratory targets, and all five
targets were examined.
Variables were considered for adjustment in the multivar-
iable regression models based on either their demonstra-
tion to be confounders (i.e., significantly associated with
both target attainment and the outcome measure) or prior
evidence of their association with the outcome. Adjust-
ment for both baseline target values (the major confound-
ers) and other confounders of the outcome was
performed. We also used models incorporating both tar-
get attainment and propensity scores for target attain-
ment. Propensity score modeling is an established
technique used to address selection bias [36]. For multiple
targets, attainment was dichotomized for the three labora-
tory targets (two or three targets versus zero or one) and
for all five targets (three or more targets attained versus
two or fewer), and propensity scores were obtained simi-
larly. Sensitivity analyses examining only those patients
who had not attained the individual target in question at
baseline and also those who had attained either no targets
or only one target at baseline were also performed. We
accounted for possible within-clinic correlation by using
conditional methods (fixed effects or stratification by
clinic) in all models presented. Likelihood ratio tests were
performed to determine each individual target's contribu-
tion to variation in the outcome of interest. Statistical sig-
nificance was set at P < 0.05. However, because examining
five targets in a small sample might lead to randomly sig-
nificant results at this cutoff, we decided to also set a Bon-
ferroni-correct threshold P value of 0.05/5 = 0.01 for theBMC Health Services Research 2007, 7:5 http://www.biomedcentral.com/1472-6963/7/5
Page 4 of 13
(page number not for citation purposes)
individual target analyses. All analyses were performed
using STATA v. 8.2 (College Station, Texas).
Results
Patient characteristics by attainment of targets
Relative to patients not attaining 6-month targets (Table
1), (i) albumin target attainers were younger, more likely
to be male, and less likely to have a fistula at the start of
hemodialysis, and had lower comorbidity scores, higher
baseline albumin and creatinine, and lower initial CRP;
(ii) Ca-P target attainers were older and less likely to be
employed or noncompliant with dialysis and had higher
comorbidity scores, higher Kt/V, lower creatinine, higher
hemoglobin, and lower initial Ca-P product; (iii) hemo-
globin target attainers were older and more likely to be
male and white and had less frequent physician visits,
lower BMI, higher Kt/V, and higher initial hemoglobin;
(iv) dialysis dose target attainers were older and less likely
to be male and had more frequent physician visits lower
BMI, lower creatinine, higher hemoglobin, lower Ca-P,
and higher initial dose (Kt/V); and (v) access target attain-
ers were younger and more likely to be male and white
and had lower dose, higher albumin, lower CRP, and
fewer fistulas (none) at start of dialysis, relative to those
not attaining the target. For those who were at or above
targets at 6 months, 26.1%, 81.2%, 23.2%, 61.5%, and
56.5% of patients were already at the albumin, Ca-P prod-
uct, hemoglobin, dialysis dose, and vascular access targets,
respectively, at baseline. Finally, those patients attaining a
greater number of targets at 6 months (Table 1) had lower
comorbidity, BMI, and CRP; and were more compliant
with dialysis and generally closer to the targets at baseline
than those who attained fewer targets (data not shown).
For those with information on all five targets (n = 344) at
6 months, 39% (n = 133) had attained 0 or 1 target at
baseline; 41%, 16%, and 4% of these patients had
attained 2, 3, and 4 or 5 targets at baseline, respectively.
Association of attainment of targets with mortality
The crude mortality rates at the median follow-up of 2.8
years were lower in the patients who attained the albumin
target and in those who attained multiple targets (Table
2). A Kaplan-Meier survival curve (Fig. 1) suggested that
those patients attaining three or more targets may have a
survival advantage over those attaining fewer or no tar-
gets.
In adjusted models, the attainment of all individual tar-
gets was associated with a decreased risk of mortality
(Table 2). These associations were statistically significant
for all individual targets except access type with usual
multivariable adjustment. Only albumin and dialysis
dose targets remained statistically significantly associated
with decreased mortality using the stricter Bonferroni-
adjusted threshold. Propensity score adjustment also
showed decreased risk of mortality with the attainment of
each target except access type, but the association of the
albumin target with mortality was no longer statistically
significant. Excluding those patients who had already
attained the individual target at baseline (giving sample
sizes of n = 558, 159, 517, 244, and 356 for albumin, Ca-
P product, hemoglobin, dialysis dose, and access type,
respectively), only albumin remained statistically signifi-
cant as a predictor of decreased mortality (data not
shown). By likelihood ratio tests in multivariable-
adjusted models, albumin and hemoglobin (P < 0.001 for
both) and Ca-P product (P = 0.039) contributed most to
the variation in mortality. Dialysis dose (P = 0.052) and
access (P = 0.806) did not significantly contribute to vari-
ation in mortality.
Attaining one or more of the laboratory targets was asso-
ciated with decreased risk of mortality (Table 2). When all
five targets were examined, only the attainment of three or
more targets was associated with decreased risk mortality,
but there was again a strong statistically significant trend
of decreased risk with each additional target attained
(Table 2). In subpopulation analyses of those attaining 0
or 1 targets at baseline, risk of mortality decreased with
additional 6-month targets attained, but the trend was not
significant (P = 0.201). When only those who attained
zero targets at baseline were included (n = 29), results
were not significant.
Association of attainment of targets with hospitalization
Incidence of hospitalization
All individual targets were associated with a decreased
incidence of hospitalizations, with the exception of attain-
ing the dialysis dose target, which was only statistically
significantly associated with decreased hospitalizations
with propensity score adjustment (Table 3). Additionally,
all targets except dialysis dose remained statistically signif-
icantly associated with decreased hospitalization inci-
dence using the Bonferroni-adjusted significance
threshold. Excluding those patients who had already
attained the individual target at baseline, all individual
targets remained statistically significantly associated with
decreased hospital admissions, except for the Ca-P prod-
uct target (P = 0.091; n = 154). By likelihood ratio test,
albumin, Ca-P, hemoglobin and access (P < 0.001 for all)
all contributed significantly to the variation in hospital
admission rate, whereas dialysis dose (P = 0.903) did not.
Each increase in number of targets attained among the
laboratory targets was associated with a statistically signif-
icantly decreased incidence of hospitalization (Table 3).
There was also a highly significant trend toward decreased
incidence with more targets attained. When all five targets
were examined, a significant trend of decreased incidence
of hospitalization with each additional target attained wasB
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Table 1: Baseline patient characteristics by attainment of 6-month clinical performance targets
Characteristic Albumin Target Attained 
(N = 650)
Ca-P Product Target 
Attained 
(N = 648)
Hemoglobin Target 
Attained 
(N = 644)
Dialysis Dose Target 
Attained 
(N = 539)
Access Target Attained 
(N = 425)
Total Number of Targets Attained 
(N = 344)
No Yes P* No Yes P* No Yes P* No Yes P* No Yes P* 0–1 2 3 4–5 P*
N (%) 451 (69) 199 (31) -- 250 (39) 398 (61) -- 256 (40) 388 (60) -- 95 (18) 444 (82) -- 310 (73) 115 (27) -- 40 (12) 116 (33) 117 (34) 71 (21) --
Demographic
Mean age 60.4 ± 13.6 56.9 ± 15.7 0.005 56.3 ± 13.8 61.1 ± 14.3 <0.001 57.4 ± 14.5 60.4 ± 14.0 0.015 55.1 ± 14.3 60.6 ± 14.1 <0.001 60.1 ± 14.5 56.1 ± 13.5 0.010 58.4 ± 12.8 58.4 ± 15.2 61.6 ± 13.3 58.4 ± 13.9 0.255
Sex (% male) 46.8 66.8 <0.001 57.6 50.0 0.059 46.9 56.7 0.015 74.7 48.7 <0.001 47.4 69.6 <0.001 57.5 43.1 51.3 74.7 <0.001
Race (% white) 59.0 64.8 0.320 65.2 58.3 0.122 55.1 64.4 0.042 61.1 58.1 0.806 57.4 68.7 0.001 65.0 56.0 55.6 67.6 0.461
Education 
(% HS grad)
65.3 72.3 0.084 68.9 66.5 0.538 65.4 68.7 0.379 67.7 66.1 0.765 67.9 67.9 0.998 65.0 62.9 68.8 70.6 0.690
Employment 
(% employed)
8.4 9.6 0.628 12.0 6.8 0.023 7.8 9.6 0.445 10.5 8.1 0.448 8.7 11.4 0.400 10.0 10.3 9.4 10.0 0.996
Clinical
Access (% fistula) 23.3 11.9 0.007 30.8 30.2 0.943 23.9 17.8 0.120 15.5 21.8 0.283 29.0 0.0 <0.001 27.5 26.7 25.6 5.6 0.003
Diabetes (% diabetic) 60.5 44.7 <0.001 56.4 55.0 0.732 59.8 52.8 0.083 62.1 55.6 0.248 59.7 47.8 0.029 62.5 62.1 63.3 39.4 0.006
ICED 
(% with score of 3)
33.7 22.6 0.003 26.1 37.1 0.008 33.2 28.9 0.503 33.7 31.1 0.151 33.6 21.7 <0.001 37.5 41.4 26.5 23.9 0.027
Late referral 
(% <4mo)
33.6 31.2 0.577 17.7 21.6 0.322 32.6 32.9 0.931 40.0 32.7 0.212 34.7 16.7 0.001 34.5 30.0 31.6 26.2 0.848
Mean BMI 27.7 ± 7.3 26.8 ± 6.3 0.144 28.1 ± 7.1 27.1 ± 6.9 0.061 28.6 ± 8.1 26.7 ± 6.0 0.001 30.5 ± 8.4 27.1 ± 6.6 <0.001 27.5 ± 7.2 27.9 ± 6.5 0.593 31.5 ± 9.8 27.7 ± 6.8 28.4 ± 6.4 25.9 ± 5.8 0.001
Physician visit 
(% weekly)
14.5 14.3 0.995 13.9 14.8 0.605 19.6 11.2 0.013 9.8 17.0 <0.001 15.0 14.3 0.663 24.6 14.1 12.3 14.8 0.213
Sit-down rounds 
(% monthly)
40.6 47.6 0.103 45.8 40.5 0.195 39.6 43.9 0.294 38.0 42.0 0.487 38.5 41.1 0.639 36.1 44.5 38.6 48.2 0.280
Dialysis compliant 
(% noncompliant)
9.4 6.4 0.211 11.4 6.7 0.040 10.8 7.1 0.102 11.6 7.0 0.134 9.0 5.2 0.198 9.0 12.4 6.6 1.2 0.008
Laboratory
Mean Kt/V 1.26 ± 0.35 1.26 ± 0.29 0.910 1.21 ± 0.33 1.28 ± 0.33 0.010 1.22 ± 0.33 1.28 ± 0.33 0.048 0.99 ± 0.28 1.29 ± 0.31 <0.001 1.30 ± 0.33 1.19 ± 0.36 0.006 1.09 ± 0.31 1.29 ± 0.33 1.20 ± 0.35 1.30 ± 0.30 0.002
Mean albumin 3.41 ± 0.45 3.68 ± 0.44 <0.001 3.47 ± 0.42 3.51 ± 0.49 0.359 3.45 ± 0.49 3.52 ± 0.44 0.074 3.43 ± 0.50 3.52 ± 0.45 0.107 3.46 ± 0.46 3.60 ± 0.42 0.003 3.42 ± 0.47 3.42 ± 0.50 3.51 ± 0.38 3.70 ± 0.43 <0.001
Mean creatinine 6.88 ± 2.20 8.37 ± 2.69 <0.001 7.85 ± 2.59 7.01 ± 2.32 <0.001 7.51 ± 2.42 7.20 ± 2.48 0.115 7.80 ± 2.49 7.17 ± 2.40 0.022 6.94 ± 2.26 7.73 ± 2.47 0.002 7.48 ± 1.96 6.83 ± 2.37 7.21 ± 2.40 7.24 ± 2.32 0.384
Mean hemoglobin 9.74 ± 1.45 9.86 ± 1.60 0.337 9.59 ± 1.46 9.89 ± 1.50 0.012 9.50 ± 1.41 9.95 ± 1.52 <0.001 9.46 ± 1.50 9.88 ± 1.50 0.013 9.73 ± 1.39 9.80 ± 1.50 0.621 9.54 ± 1.33 9.60 ± 1.35 9.71 ± 1.44 10.2 ± 1.46 0.022
Mean Ca-P product 45.8 ± 14.3 47.9 ± 14.4 0.091 50.8 ± 14.6 43.8 ± 13.5 <0.001 46.9 ± 15.2 46.2 ± 13.7 0.516 48.8 ± 14.3 45.6 ± 14.1 0.043 46.2 ± 14.9 47.6 ± 13.6 0.388 53.8 ± 15.8 44.4 ± 14.2 46.9 ± 14.5 43.5 ± 12.0 0.001
Median CRP (IQR) 4.4(2.1,12.8) 3.4 (1.3,5.5) <0.001 3.9(1.6,12.0) 4.0 (1.8,9.4) 0.461 4.3 (2.1,13) 3.8 (1.7,7.5) 0.482 4.6 (2.6,14) 3.8 (1.6,9.4) 0.942 3.9 (2.0,12) 3.4 (1.4,5.8) 0.035 5.5 (3.5,14.7) 3.5 (1.6,10.6) 3.6 (1.9,6.5) 3.6 (1.3,5.4) 0.020
Median ferritin (IQR) 118 (63,261) 143 (67,272) 0.572 117 (66,268) 142 (63,265) 0.312 154 (70,317) 119 (62,247) 0.078 118 (62,266) 133 (65,260) 0.817 130 (63,268) 126 (57,243) 0.366 214 (99,358) 118 (57,232) 88 (43,181) 167 
(108,292)
<0.001
Note that our patients were quite similar in most characteristics to the general U.S. 2002 incident hemodialysis population (our cohort vs. U.S.): % aged 65 or older, 39.8% vs. 52.3%; % white: 60.3% vs. 
63.5%; % male, 53.6% vs. 54.3%; % diabetes as cause of end-stage renal disease, 47.3 vs. 45.0%; mean body mass index, 27.5 vs. 27.5; mean albumin 3.5 vs. 3.1 g/dl, mean hemoglobin, 9.8 vs. 10.0 g/dl; and mean 
creatinine, 7.3 vs. 7.1 [28].
ICED = Index of Coexistent Disease, scored on a 3-point scale (0 = no, 1 = mild, 2 = moderate, 3 = severe comorbidity); BMI = body mass index; Ca-P = calcium phosphate; CRP = C-reactive protein; IQR 
= interquartile range.
*By analysis of variance/t test (continuous variables) or χ2 test (categorical variables).BMC Health Services Research 2007, 7:5 http://www.biomedcentral.com/1472-6963/7/5
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seen (Table 3). Only the attainments of three or more tar-
gets were individually associated with significantly
decreased hospitalization incidence, relative to attaining
one or none of the targets. In subpopulation analyses of
those attaining 0 or 1 targets at baseline, hospital admis-
sions decreased even more strikingly with each additional
6-month target attained [IRR = 2 targets, 0.70 (0.55–
0.89); 3 targets, 0.51 (0.40–0.65); 4 or 5 targets, 0.28
Table 2: Association of attainment of 6-month clinical performance targets with mortality
Target % Dead* Relative Hazard (95% Confidence Interval)
Unadjusted Multivariate Adjusted** Propensity Score Adjusted***
Individual Targets
Albumin ≥4.0 g/dl (N = 650)
Target not attained 29.9 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
Target attained 16.1 0.49 (0.37–0.65) 0.55 (0.41–0.75) 0.77 (0.55–1.08)
P <0.001 <0.001 <0.001 0.132
Ca-P Product <55 mg2/dl2 (N = 648)
Target not attained 24.4 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
Target attained 26.4 0.83 (0.65–1.04) 0.74 (0.57–0.95) 0.67 (0.52–0.86)
P0 . 5 7 4 0 . 1 0 9 0.020 0.002
Hemoglobin ≥11 g/dl (N = 644)
Target not attained 29.3 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
Target attained 23.2 0.75 (0.60–0.96) 0.62 (0.48–0.79) 0.67 (0.52–0.87)
P0 . 0 8 3 0.020 <0.001 0.002
Dialysis Dose, Kt/V≥1.2 (N = 539)
Target not attained 30.5 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
Target attained 24.8 0.73 (0.51–1.05) 0.67 (0.45–1.00) 0.56 (0.35–0.88)
P0 . 2 4 5 0 . 0 8 9 0.049 0.012
Access Type, fistula (N = 424)
Target not attained 24.5 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
Target attained 20.0 0.80 (0.57–1.11) 0.96 (0.67–1.36) 1.05 (0.73–1.52)
P 0.328 0.189 0.806 0.776
Albumin, Ca-P, and Hemoglobin Targets (N = 643)
0 targets attained 29.9 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
1 target attained 28.7 0.81 (0.56–1.16) 0.77 (0.52–1.13) 0.65 (0.44–0.95)
2 targets attained 25.7 0.61 (0.41–0.89) 0.51 (0.34–0.77) 0.49 (0.32–0.73)
3 targets attained 12.9 0.32 (0.19–0.53) 0.27 (0.15–0.47) 0.26 (0.15–0.46)
P for trend 0.009 <0.001 <0.001 <0.001
All Five Targets (N = 344)
0–1 targets attained 27.5 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
2 targets attained 29.3 0.93 (0.52–1.63) 0.90 (0.50–1.63) 0.93 (0.52–1.67)
3 targets attained 20.5 0.51 (0.28–0.91) 0.49 (0.27–0.91) 0.53 (0.29–0.97)
4–5 targets attained 15.5 0.37 (0.19–0.72) 0.33 (0.16–0.63) 0.41 (0.20–0.83)
P for trend 0.030 <0.001 <0.001 <0.001
Mean at-risk follow-up was 3.3 years (median, 2.8 years). Statistically significant values are in boldface type.
*At median follow-up (2.8 years). P by Pearson's χ2 test (individual targets) or nonparametric trend test (multiple targets).
**Adjusted for first value of target(s) indicated, age, race, index of co-existent disease, and albumin.
***Propensity score models consisted of:
Albumin target: age, sex, index of co-existent disease, baseline albumin, creatinine, and C-reactive protein;
Ca-P target: age, sex, employment, index of co-existent disease, creatinine, hemoglobin, and baseline Ca-P;
Hemoglobin target: age, sex, race, body mass index, and baseline hemoglobin;
Dialysis dose target: age, sex, race, body mass index, Kt/V, creatinine, hemoglobin, and Ca-P;
Access target: age, sex, race, index of co-existent disease, albumin, creatinine, and C-reactive protein;
Albumin, Ca-P, and hemoglobin targets: age, sex, index of co-existent disease, body mass index, baseline albumin, baseline hemoglobin, baseline Ca-
P, and C-reactive protein; and
All five targets: age, sex, index of co-existent disease, body mass index, baseline Kt/V, baseline albumin, baseline hemoglobin, baseline Ca-P, and C-
reactive protein.BMC Health Services Research 2007, 7:5 http://www.biomedcentral.com/1472-6963/7/5
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(0.16–0.50); P for trend<0.001]. With only those patients
who did not attain any targets at baseline (n = 23), results
were not significant (P = 0.435). Again, history of cardio-
vascular disease was significantly associated with hospital
admissions, but adjusting for it did not change our results.
Less frequent physician contact, less frequent sit-down
rounds, and noncompliance were all associated with
increased hospital admissions but did not affect our esti-
mates of the association of targets with hospital admis-
sions when they were added as adjusters.
Days hospitalized
All individual targets except dialysis dose were associated
with a decreased hospital days (Table 3), but propensity
score adjustment showed a statistically significant
decrease in hospital days with the attainment of the dial-
ysis dose target. Additionally, all individual targets
remained statistically significantly associated with
decreased hospital days using the Bonferroni-adjusted sig-
nificance threshold. Excluding those patients who had
already attained the individual target at baseline, all indi-
vidual targets remained statistically significantly associ-
ated with decreased hospital days (P < 0.001 for all). By
likelihood ratio test, all five individual targets (P < 0.001
for all) all contributed significantly to the variation in
number of days hospitalized.
Each increase in number of targets attained among the
laboratory targets was associated with decreased hospital-
ized days (Table 3), and there was a significant trend
toward fewer days with more targets attained. The same
statistically significant trend of decreased hospital days
with each additional target attained was seen when all five
targets were examined (Table 3). Subpopulation analyses
of those attaining 0 or 1 targets at baseline showed similar
results to hospital admissions [IRR = 2 targets, 0.68 (0.62–
0.74); 3 targets, 0.55 (0.50–0.61); 4 or 5 targets, 0.15
(0.11–0.20); P for trend<0.001]. Only including those
patients who did not attain any targets at baseline (n = 23)
still gave a significant trend (P = 0.030) toward decreased
hospital days with more targets attained at 6 months.
Hospitalization costs
The attainment of the albumin target was associated with
a reduction of approximately $3000 per patient-year in
Medicare hospital payments (Table 4) with multivariable
adjustment. This target remained statistically significantly
with a reduction in payment using the Bonferroni-
adjusted significance threshold. With the use of propen-
sity score adjustment, decreased payments were seen with
all individual targets, but without statistical significance
(Table 4). By likelihood ratio test, albumin (P = 0.002)
and access (P = 0.039) contributed to variation in hospital
costs, but Ca-P product (P = 0.977), hemoglobin (P =
0.679), and dialysis dose (P = 0.535) did not.
Increases in the number of targets attained among the lab-
oratory targets were generally associated with decreased
payments (Table 4). Also, there was a trend toward
decreased payments with more targets attained. The trend
of decreased payments with each additional target
attained was also seen when all five targets were examined
(Table 4), but statistical significance was borderline in the
adjusted model. Propensity score adjustment showed
results similar to those obtained with multivariate adjust-
ment (P for trend = 0.129 for all five targets). Subpopula-
tion analyses of those attaining 0 or 1 targets at baseline
showed that hospital payments decreased with each addi-
tional 6-month target attained ($15,835, $12,708,
$11,499, and $10,938 for 0 or 1, 2, 3, and 4 or 5 targets,
respectively), but the trend was not significant (P =
0.470).
Discussion
Attainment of clinical performance targets in patients
requires considerable time and effort on the part of pro-
viders and patients. Resistance to work on quality
improvement may in part be due to skepticism that attain-
ment will lead to meaningful improvement in health and
other outcomes [2,3]. This national longitudinal study
shows that attainment of each of the individual targets is
strongly associated with better outcomes, including
decreased mortality, fewer hospitalizations, fewer days in
the hospital, and lower overall Medicare hospital pay-
ments, validating the professional clinical practice guide-
lines [4]. A few studies of prevalent hemodialysis patients
have shown associations of clinical performance target
attainment with decreased hospital admissions and
related costs [37,38], but this study adds to our knowledge
Cumulative mortality by number of KDOQI clinical perform- ance targets attained at 6 months Figure 1
Cumulative mortality by number of KDOQI clinical perform-
ance targets attained at 6 months. P = 0.002 by log-rank test.BMC Health Services Research 2007, 7:5 http://www.biomedcentral.com/1472-6963/7/5
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Table 3: Association of attainment of 6-month clinical performance targets with hospital admissions and hospital days
Target Average per follow-up year* Incidence Rate Ratio (95% Confidence Interval)
Unadjusted Multivariate Adjusted** Propensity Score Adjusted***
NUMBER OF HOSPITALIZATIONS
Individual Targets
Albumin ≥4.0 g/dl (N = 650)
Target not attained 2.2 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
Target attained 1.4 0.62 (0.57–0.67) 0.67 (0.62–0.73) 0.81 (0.73–0.89)
P <0.001 <0.001 0.001 <0.001
Ca-P Product <55 mg2/dl2 (N = 648)
Target not attained 2.1 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
Target attained 1.9 0.88 (0.82–0.95) 0.86 (0.79–0.92) 0.80 (0.74–0.86)
P 0.374 0.001 <0.001 <0.001
Hemoglobin ≥11 g/dl (N = 644)
Target not attained 2.1 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
Target attained 1.8 0.85 (0.79–0.91) 0.82 (0.76–0.88) 0.81 (0.75–0.87)
P0 . 1 4 6 <0.001 <0.001 <0.001
Dialysis Dose, Kt/V≥1.2 (N = 539)
Target not attained 1.9 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
Target attained 1.9 1.00 (0.89–1.13) 0.99 (0.88–1.12) 0.86 (0.75–0.99)
P 0.796 0.970 0.902 0.040
Access Type, fistula (N = 424)
Target not attained 2.0 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
Target attained 1.4 0.73 (0.66–0.81) 0.79 (0.71–0.88) 0.86 (0.77–0.97)
P 0.016 <0.001 <0.001 0.011
Albumin, Ca-P, and Hemoglobin Targets (N = 643)
0 targets attained 2.6 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
1 target attained 2.1 0.69 (0.61–0.76) 0.69 (0.62–0.78) 0.59 (0.53–0.66)
2 targets attained 1.8 0.62 (0.56–0.70) 0.62 (0.55–0.69) 0.57 (0.51–0.65)
3 targets attained 1.3 0.43 (0.37–0.50) 0.44 (0.38–0.51) 0.39 (0.33–0.46)
P for trend <0.001 <0.001 <0.001 <0.001
All Five Targets (N = 344)
0–1 targets attained 2.4 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
2 targets attained 2.3 0.96 (0.82–1.14) 0.88 (0.74–1.05) 1.01 (0.85–1.19)
3 targets attained 1.7 0.71 (0.60–0.84) 0.67 (0.57–0.80) 0.76 (0.64–0.90)
4–5 targets attained 1.1 0.55 (0.45–0.66) 0.55 (0.43–0.67) 0.65 (0.53–0.80)
P for trend <0.001 <0.001 <0.001 <0.001
DAYS HOSPITALIZED
Individual TargetsBMC Health Services Research 2007, 7:5 http://www.biomedcentral.com/1472-6963/7/5
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Albumin ≥4.0 g/dl (N = 647)
Target not attained 13.0 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
Target attained 7.4 0.55 (0.53–0.57) 0.61 (0.58–0.63) 0.76 (0.72–0.79)
P <0.001 <0.001 <0.001 <0.001
Ca-P Product <55 mg2/dl2 (N = 645)
Target not attained 11.6 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
Target attained 11.1 0.89 (0.87–0.92) 0.85 (0.83–0.88) 0.79 (0.77–0.82)
P0 . 7 1 9 <0.001 <0.001 <0.001
Hemoglobin ≥11 g/dl (N = 641)
Target not attained 11.7 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
Target attained 11.0 0.92 (0.90–0.95) 0.89 (0.86–0.92) 0.89 (0.86–0.91)
P0 . 5 7 1 <0.001 <0.001 <0.001
Dialysis Dose, Kt/V≥1.2 (N = 537)
Target not attained 9.3 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
Target attained 11.6 1.12 (1.06–1.18) 1.11 (1.05–1.17) 0.89 (0.84–0.95)
P0 . 2 2 5 <0.001 <0.001 <0.001
Access Type, fistula (N = 420)
Target not attained 12.3 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
Target attained 7.3 0.65 (0.62–0.67) 0.72 (0.69–0.75) 0.79 (0.75–0.82)
P 0.004 <0.001 <0.001 <0.001
Albumin, Ca-P, and Hemoglobin Targets (N = 640)
0 targets attained 13.9 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
1 target attained 11.7 0.69 (0.66–0.72) 0.70 (0.67–0.73) 0.61 (0.59–0.64)
2 targets attained 11.9 0.70 (0.67–0.73) 0.70 (0.66–0.73) 0.67 (0.63–0.70)
3 targets attained 6.0 0.37 (0.34–0.39) 0.37 (0.35–0.40) 0.35 (0.33–0.38)
P for trend 0.001 <0.001 <0.001 <0.001
All Five Targets (N = 341)
0–1 targets attained 13.2 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
2 targets attained 14.3 0.95 (0.89–1.01) 0.87 (0.82–0.94) 1.00 (0.94–1.07)
3 targets attained 10.4 0.71 (0.66–0.75) 0.67 (0.63–0.72) 0.77 (0.72–0.83)
4–5 targets attained 4.8 0.41 (0.38–0.44) 0.43 (0.40–0.47) 0.50 (0.46–0.55)
P for trend <0.001 <0.001 <0.001 <0.001
For hospital admissions, mean at-risk follow-up (excluding days in the hospital when patients could not be admitted) was 3.1 years (median, 3.0 
years); for hospital days, mean at-risk follow-up was 3.2 years (median, 3.1 years). Statistically significant values are in boldface type.
*P by t test (individual targets) or nonparametric trend test (multiple targets).
**Adjusted for first value of target(s) indicated, age, race, index of co-existent disease, and albumin.
***Propensity score models consisted of:
Albumin target: age, sex, index of co-existent disease, baseline albumin, creatinine, and C-reactive protein;
Ca-P target: age, sex, employment, index of co-existent disease, creatinine, hemoglobin, and baseline Ca-P;
Hemoglobin target: age, sex, race, body mass index, and baseline hemoglobin;
Dialysis dose target: age, sex, race, body mass index, Kt/V, creatinine, hemoglobin, and Ca-P;
Access target: age, sex, race, index of co-existent disease, albumin, creatinine, and C-reactive protein;
Albumin, Ca-P, and hemoglobin targets: age, sex, index of co-existent disease, body mass index, baseline albumin, baseline hemoglobin, baseline Ca-
P, and C-reactive protein; and
All five targets: age, sex, index of co-existent disease, body mass index, baseline Kt/V, baseline albumin, baseline hemoglobin, baseline Ca-P, and C-
reactive protein.
Table 3: Association of attainment of 6-month clinical performance targets with hospital admissions and hospital days (Continued)BMC Health Services Research 2007, 7:5 http://www.biomedcentral.com/1472-6963/7/5
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of the effect of clinical performance target attainment in
incident hemodialysis patients. Importantly, our results
also provide new evidence that each additional target
attained results in incremental improvement in these out-
comes, regardless of which targets are attained, and pro-
vide a comprehensive examination of a variety of
performance measures and outcomes.
For example, we found that attainment of each additional
target resulted in a mortality risk reduction of approxi-
mately 35%, a hospitalization risk reduction of approxi-
mately 20%, a reduction in number of days hospitalized
of approximately 24%, and a decrease in annual Medicare
hospital payments of approximately $762 per patient-
year. The results support the idea that efforts to improve
clinical performance (e.g., through provider education,
competition from public reporting, and rewards, such as
payment for performance) might reap large benefits in
morbidity, mortality, and efficiency for both patients and
payers.
Table 4: Association of attainment of 6-month clinical performance targets with hospital payments
Target Average Cost per Follow-up Year
Crude* Unadjusted Multivariate Adjusted**
Individual Targets
Albumin ≥4.0 g/dl (N = 470)
Target not attained $14,252 $14,333 $9,838
Target attained $9,406 $9,259 $6,556
P 0.001 0.001 0.002
Ca-P Product <55 mg2/dl2 (N = 469)
Target not attained $13,325 $13,086 $11,586
Target attained $12,469 $12,608 $11,549
P 0.553 0.747 0.978
Hemoglobin ≥11 g/dl (N = 466)
Target not attained $13,163 $12,833 $8,511
Target attained $12,456 $12,659 $8,125
P 0.621 0.906 0.691
Dialysis Dose, Kt/V≥1.2 (N = 390)
Target not attained $13,774 $14,589 $9,126
Target attained $12,290 $12,160 $8,155
P 0.495 0.300 0.553
Access Type, fistula (N = 308)
Target not attained $13,148 $13,384 $13,923
Target attained $10,111 $9,538 $9,936
P0 . 1 0 9 0.044 0.052
Albumin, Ca-P, and Hemoglobin Targets (N = 465)
0 targets attained $15,535 $15,534 $7,877
1 target attained $13,980 $13,815 $7,388
2 targets attained $11,439 $11,228 $5,870
3 targets attained $10,461 $11,596 $6,235
P for trend 0.007 0.060 0.088
All Five Targets (N = 248)
0–1 targets attained $12,453 $13,285 $3,165
2 targets attained $15,366 $14,919 $3,670
3 targets attained $10,389 $10,446 $2,645
4–5 targets attained $8,654 $8,624 $2,138
P for trend 0.029 0.029 0.052
Mean follow-up was 2.8 years (median, 2.7 years). Statistically significant values are in boldface type. Cost per year was log-transformed; averages of 
log-transformed cost were calculated (either crudely or using linear regression models), and the averages were exponentiated to reflect dollar 
values.
*P by t test (individual targets) or nonparametric trend test (multiple targets).
**Adjusted for first value of target(s) indicated, age, race, index of co-existent disease, and albumin.BMC Health Services Research 2007, 7:5 http://www.biomedcentral.com/1472-6963/7/5
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It could be argued that our data are historical and no
longer relevant in today's quality improvement-oriented
atmosphere. However, recent reports from CMS and the
USRDS on the clinical performance of hemodialysis
patients in the United States show that 91%, 35%, 80%,
and 39% of patients attained Kt/V≥1.2, fistula use, hemo-
globin ≥ 11 g/dl, and albumin ≥ 4.0 g/dl, respectively, in
the last quarter of 2003 [39,40]. These percentages are
higher than those seen in this study (82%, 27%, 60%, and
31%, respectively), but clearly there is still room for
improvement in the attainment of these targets.
Although this study was observational, the associations
we report do meet many of the criteria for causality,
including plausibility, temporality, dose-response rela-
tionship, and consistency. It is certainly plausible that
attaining clinical performance targets would improve
patient outcomes, and it is just as plausible that increasing
numbers of targets attained in a patient would result in
incrementally better outcomes. The use of an incident
dialysis cohort, capturing patients at the inception of their
dialysis treatment, ensures temporality, as the exposure to
provider efforts to meet clinical performance targets for
ESRD patients begins with the initiation of kidney
replacement therapy. We observed a dose-response rela-
tionship, reflected in the graded trend toward better out-
comes with more targets attained. Also, our results were
consistent across various modeling strategies and consist-
ent with other studies focusing on single static measures
(e.g., albumin) or outcomes (e.g., mortality).
If this assumption of a causal relationship holds, and if we
assume that our population is similar to the general U.S.
hemodialysis population in the distribution of targets
attained and other characteristics, projected outcomes on
a population level are that each additional performance
target attained could potentially save 20,440 lives,
113,400 hospital admissions, 952,000 hospital days, and
$213 million in Medicare hospital payments in a year.
These estimates confirm that there is tremendous poten-
tial value in patients attaining multiple targets, not only
for decreased mortality, as reported previously [21], but in
reduced hospitalizations, length of stay, and associated
cost.
What does it take to move toward a better level of per-
formance? Many methods have been and are being
attempted. First, performance measurement with feed-
back to providers has produced demonstrable, but mod-
est, gains. Demonstration of explicit links to health
outcomes, such as the results we generated, might further
help to convince providers of the importance of better
clinical performance. Second, providing performance
results and evidence of its link to outcome to consumers
or patients could stimulate providers to improve [41-43].
Finally, paying providers for better performance is in its
infancy but is rapidly gaining momentum [44,45]. These
results provide a firmer foundation for the application of
the performance measures that we studied to reward pro-
viders for attaining or improving good outcomes. To the
extent that our data on hospital payments are true, they
may also provide a rationale to return a finite portion of
insurer savings on hospital care to providers, rather than
rewarding high performers at the expense of other provid-
ers.
Some possible limitations to this study deserve mention.
First, this study was underpowered to determine which
particular individual targets or combinations among the
five performance targets examined yield the most benefit
in terms of each outcome. Second, it should be remem-
bered that this is an observational study and that only the
associations between target and outcome can be ascer-
tained, not cause and effect. Despite the fact that some
clinical performance targets have been chosen based upon
observational data and consensus (and could never be
part of an ethical randomized trial), the value of observa-
tional data should not be overstated. Because some of the
factors that we studied here were not the subject of
national guidelines at the time we started our study,
guideline-directed therapeutic intent cannot be shown.
The hemoglobin, dialysis dose, and vascular access targets
were in place in 1997 and have not changed since this
time, although they were not yet widely implemented by
1998. The albumin and Ca-P targets used here were not
introduced until well after the study period. Third, as with
any study of clinical performance targets, the biological
markers studied may be influenced by other factors than
the quality of providers' care. For example, albumin and
hemoglobin levels could be affected in part by the degree
of ultrafiltration achieved. Of course, some targets may be
more easily modified (e.g., hemoglobin through erythro-
poietin) than others (e.g., albumin, which is influenced by
patients' nutritional and inflammatory states). Impor-
tantly, there may be fixed and possibly unmeasurable
patient characteristics that might or might not allow target
attainment with exposure to same quality of provider
care. Such characteristics might also affect the amount of
time needed to attain a goal, which may be more or less
than 6 months for some patients and some targets.
Finally, despite collection of and adjustment with exten-
sive data on determinants of patient outcomes, selection
bias and residual confounding due to lack of data on var-
iables for which we could not account may still exist.
Conclusion
This study strongly suggests that clinical performance tar-
get attainment is associated with better patient outcomes,
including decreased hospitalization, hospital days, and
associated costs and better survival. Providers treatingBMC Health Services Research 2007, 7:5 http://www.biomedcentral.com/1472-6963/7/5
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chronic disease should be reassured that local and
national efforts expended to attain incremental change in
the number of performance targets reached results in
additional benefit to patients.
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